2024-520177-12-00Not yet recruitingPhase 3
An assessment of the effect of 1 dose with oxymetazoline nasal spray(Otrivin®) on the physical capacity of patients suffering from Chronic Obstructive Pulmonary Disease (COPD)
A single group treatment, phase 4, study to assess the effect of 1 dose with oxymetazoline nasal spray(Otrivin®) on physical capacity of males and females aged 18 and 64 years suffering from Chronic Obstructive Pulmonary Disease (COPD)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 24 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To assess the effect of 1 dose with oxymetazoline nasal spray(Otrivin®) on the physical capacity of patients suffering from Chronic Obstructive Pulmonary Disease (COPD)
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- First submitted
- 19 Dec 2024
- Start date
- 4 Oct 2021
- Lead sponsor
- Sorlandet Sykehus HF
- Diseases
- COPD
- EU CT number
- 2024-520177-12-00
- EudraCT number
- 2020-005013-40
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 64
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- Active malignant disorders
- Other obstructive pulmonary disorders.
Other
- Pragnancy
Who the study is looking for
- Participants who comply with the standard diagnostic criteria for Chronic Obstructive Pulmonary Disease, COPD, as defined in the GOLD standard (Shireen M. 2028)
Age in the registry: 18 years to 64 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Akershus University Hospital | Loerenskog | Norway | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.